Needham Maintains Buy on Globus Medical, Lowers Price Target to $100
Needham analyst David Saxon maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $117 to $100.
Share
Why It Matters
An expert analyst still likes Globus Medical stock but thinks it might be worth less money soon. You can watch if other experts agree or if the company's business news changes their minds.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.